Introduction {#sec1_1}
============

Arterial stiffness is a well-established independent marker of cardiovascular risk in hypertensive patients and even in healthy individuals \[[@B1],[@B2]\]. Arterial stiffness is a complex phenomenon consisting of several distinct processes including structural elements within the arterial wall, vascular smooth muscle tone, chronic low-grade inﬂammation, and endothelial dysfunction \[[@B3],[@B4]\]. It is also known that several cardiovascular risk factors including age, smoking, hypertension, hypercholesterolemia, metabolic syndrome and type II diabetes are associated with increased arterial stiffness \[[@B4]\]. Thus, there is interest in factors affecting arterial stiffness as a strong indicator for development of cardiovascular disease.

Calcification of the mitral valve, known as mitral annular calcification (MAC), results from a chronic degenerative noninflammatory process. Previous studies have documented that patients with MAC have higher prevalences of atherosclerotic risk factors and different forms of atherosclerotic cardiovascular diseases \[[@B5],[@B6]\]. It seems that the etiological process of increased arterial stiffness and MAC has large overlaps. Also MAC is suggested to be associated with left atrial dilatation \[[@B7]\], aortic atheroma \[[@B6]\] and impaired coronary microvascular function \[[@B8]\]. However, the potential association between MAC and arterial stiffness has not been thoroughly documented. Therefore, the aim of this study was to investigate whether an association exists between MAC and arterial stiffness.

Subjects and Methods {#sec1_2}
====================

The study was performed between January and December 2009. All patients admitted to the Department of Cardiology, outpatient clinic of the Karadeniz Technical University Hospital, with echocardiography during this period were considered. Of these, 42 consecutive patients with MAC were prospectively enrolled in this study. Forty-one age- and gender-matched individuals were the control group. Detailed medical history, physical examination and routine biochemical tests were performed in addition to 12-lead electrocardiograms. Valvular functions, left ventricular (LV) size and functions (ejection fraction), and left atrial diameter were evaluated by transthoracic echocardiography, as previously described \[[@B9]\]. The protocol of this study was approved by the Institution\'s Ethics Committee and written informed consent was obtained from each patient. Patients with hemolytic, inflammatory, malign, pulmonary, hepatic, and renal diseases, heart failure, valvular heart disease, congenital heart disease, ejection fraction less than 50%, history of coronary artery disease or acute coronary syndromes, history of cardiac surgery, atrial fibrillation, and current pregnancy were excluded from the study.

Echocardiographic Examination {#sec2_1}
-----------------------------

GE VingMed System 7 (Horten, Norway) was used to perform the echocardiographic examinations. The LV diameters were measured by using the American Society of Echocardiography M-mode technique \[[@B9]\]. Global LV function was assessed by measuring LV end-diastolic and end-systolic volumes and LV ejection fraction, using the modified biplane Simpson rule. Valvular heart disease was also assessed. MAC was defined as the presence of an intense echo-producing structure located at the level of the mitral annulus and in the atrioventricular groove by both 2-dimensional and M-mode echocardiographic findings on parasternal and apical views as described previously \[[@B10]\].

Measurement of Pulse Wave Velocity {#sec2_2}
----------------------------------

Aortic pulse wave velocity (PWV) was determined with the foot-to-foot method using the SphygmoCor system (AtCor Medical, Sydney, Australia) \[[@B4]\]. Consecutive recordings of the carotid and femoral artery pulse waves were collected in an electrocardiogram-based manner and thus, the time latency between the appearance of each respective waves was calculated. The distance between the two sites was measured on the body surface. The total distance between the carotid and femoral sites was used for the measurements. The average measurement over a period of 8 s (9--10 cardiac cycles) was calculated after the exclusion of extreme values.

Pressure Waveform Analysis {#sec2_3}
--------------------------

Assessment of arterial wall properties and wave reflection characteristics was performed noninvasively using the SphygmoCor system. Radial artery pressure waveforms were recorded at the wrist, using applanation tonometry with a high-fidelity micromanometer (Millar Instruments, Houston, Tex., USA). After 20 sequential waveforms had been acquired and averaged, a validated generalized mathematical transfer function was used to synthesize the corresponding central aortic pressure waveform \[[@B11]\]. The AIx and augmentation pressure (AP) were derived from this with the technique of pressure waveform analysis \[[@B4]\]. The merging point of the incident and the reflected wave (the inflection point) was identified on the generated aortic pressure waveform. AP was the maximum systolic blood pressure minus pressure at the inflection point. The AIx was defined as the AP divided by pulse pressure and expressed as a percentage. Larger values of AIx indicate increased wave reflection from the periphery or earlier return of the reflected wave as a result of increased PWV (attributable to increased arterial stiffness). The AIx is dependent upon the elastic properties of the entire arterial tree (elastic and muscular arteries). In addition, because AIx is influenced by heart rate, an index normalized to a heart rate of 75 bpm (AIx\@75) was used in accordance with Wilkinson et al. \[[@B12]\]. Only high-quality recordings, defined as an in-device quality index of \>80% (derived from an algorithm including average pulse height, pulse height variation, diastolic variation, and the maximum rate of rise of the peripheral waveform), and acceptable curves on visual inspection, were included in the analysis. All measurements were performed by the same person with the patient in the supine position in a quiet temperature-controlled room after a brief rest period of at least 5 min.

Statistical Analyses {#sec2_4}
--------------------

Continuous data are expressed as mean ± SD. Comparison between two groups was performed using the unpaired t test or nonparametric means test (Mann-Whitney U test) for continuous variables, and the Fisher exact test for categoric variables. Correlations between variables were evaluated by calculation of the Pearson correlation coefficient. Multiple linear regression analysis was used to identify significant determinants of arterial stiffness parameters (AIx\@75, PWV). For multiple regressions, factors showing a value of p \< 0.1 in univariate analysis were selected. A p value of \<0.05 was considered statistically significant. Statistical analyses were performed using SPSS software (version 10.0, SPSS, Chicago, Ill., USA).

Results {#sec1_3}
=======

Patient Characteristics {#sec2_5}
-----------------------

Baseline clinical and demographic characteristics of the study population are given in table [1](#T1){ref-type="table"}. There were no significant differences between the groups in terms of age, gender, smoking status, heart rate, body mass index, fasting glucose, serum creatinine, and lipid profiles. There was no difference between the groups with respect to medication usage. Despite the distribution of number of hypertensive individuals in both groups being designed as equal, the systolic blood pressure values of the MAC group were significantly higher (138 ± 18 mm Hg) than those of the control group (129 ± 18 mm Hg) (p = 0.02).

Baseline Echocardiographic Characteristics {#sec2_6}
------------------------------------------

There were no significant differences between the groups with respect to LV end-systolic diameter (29 ± 6 vs. 29 ± 4 mm, p = 0.62), LV end-diastolic diameter (45 ± 4 vs. 46 ± 3 mm, p = 0.17), LV end-systolic volume (28 ± 9 vs. 31 ± 11 ml, p = 0.17), LV end-diastolic volume (76 ± 18 vs. 80 ± 15 ml, p = 0.22) and ejection fraction (65 ± 5 vs. 65 ± 4%, p = 0.8). Patients with MAC had a greater posterior wall (12 ± 2 vs. 11 ± 1 mm, p = 0.002), interventricular septum (11 ± 1 vs. 10 ± 1 mm, p = 0.001) and left atrial diameter (38 ± 4 vs. 36 ± 4 mm, p = 0.03) than controls.

Pulse Wave Analysis and Velocity {#sec2_7}
--------------------------------

The indices of arterial stiffness and wave reflections of the study population are presented in table [2](#T2){ref-type="table"}. Central aortic systolic and diastolic pressure, AP and AIx\@75 (fig. [1](#F1){ref-type="fig"}) were similar between the groups. Aortic PWV values (fig. [2](#F2){ref-type="fig"}) were significantly higher in patients with MAC than control subjects.

Determinants of PWV {#sec2_8}
-------------------

In bivariate correlation analysis, significant correlations were found between PWV and brachial systolic blood pressure (r = 0.31, p = 0.003), brachial diastolic blood pressure (r = 0.2, p = 0.06), brachial mean pressure (r = 0.21, p = 0.05), aortic systolic blood pressure (r = 0.24, p = 0.02) and aortic mean pressure (r = 0.21, p = 0.05; table [3](#T3){ref-type="table"}). Also PWV values did not differ between smokers and nonsmokers, genders, and current medication (table [4](#T4){ref-type="table"}). Multiple regression analyses were performed for identifying factors that determine the PWV. Significant determinants of PWV were brachial diastolic blood pressure (β = 1.87, p = 0.04) and MAC (β = 0.41, p = 0.0001).

Discussion {#sec1_4}
==========

PWV as an index of large arterial stiffness was higher in subjects with MAC; however, AIx\@75 as a composite marker of wave reflections and arterial stiffness was similar in both groups and MAC was independent of the higher value of PWV.

The findings that MAC and brachial diastolic blood pressure were independent determinants of PWV confirmed previous observations that showed an association between blood pressure and PWV \[[@B1],[@B3]\]. Although the number of allocated hypertensive patients was similar in both groups, brachial systolic blood pressure was significantly higher in subjects with MAC than in controls. However, the difference between the central aortic pressure values of the groups was not statistically significant. Both the univariate and multivariate analyses yielded a significant relationship between MAC and PWV, but this relationship could not be explained by systolic high blood pressures in subjects with MAC.

Several mechanisms may explain the determined relationship between MAC and PWV. In previous studies, MAC was reported to be associated with both coronary risk factors and cardiovascular diseases \[[@B5],[@B6],[@B13]\]. These results clearly indicated significant associations between both cardiovascular risk factors and different measures of subclinical atherosclerosis and valvular calcification, thereby providing additional evidence for the hypothesis that annular calcification is atherosclerotic in nature \[[@B14]\]. In addition, MAC might be accepted as a manifestation of atherosclerosis because it shares similar histopathological findings \[[@B15]\]. Adler et al. \[[@B5]\] showed the presence of foam cells on the posterior mitral leaflet in patients with MAC. We cannot explain the observed association between mitral annulus calcification, a noninflammatory process, and atherosclerosis, a prominent inflammatory process, in this study. However, Fox et al. \[[@B16]\] showed that inflammatory markers were elevated in patients with valvular calcium. Although we have not measured inflammatory parameters in the current study, the above-mentioned processes indicate that some changes may also take place in MAC. It is also well known that atherosclerotic changes in vascular tissue are related to arterial stiffness \[[@B17],[@B18]\]. Increased arterial stiffness may be associated with atherosclerotic changes in subjects with MAC. An additional important mechanism that should also be considered in MAC is calcification \[[@B19]\]. Indeed patients with MAC had been reported to have increased vascular calcification \[[@B20]\], which takes place through complex yet undeciphered mechanisms that cause structural changes in large arteries \[[@B21]\]. Because it has been established that vascular calcification leads to increased PWV \[[@B22],[@B23]\], it is conceivable that patients with MAC could have increased PWV.

The measurement of aortic PWV is generally accepted as the most simple, noninvasive, reproducible model for determining arterial stiffness; hence, it is considered as the 'gold standard' measurement of arterial stiffness \[[@B4]\]. It has also been used in epidemiological studies demonstrating the predictive value of aortic stiffness for cardiovascular events \[[@B24],[@B25]\]. Our finding that MAC was significantly associated with PWV but not with AIx\@75. This is in agreement with previous studies \[[@B26],[@B27]\] showing that aortic stiffness and wave reflection indices do not always change in parallel. Gedikli et al. \[[@B26]\] reported that low total antioxidant capacity levels were associated with AIx\@75 but not with PWV \[[@B26]\]. Furthermore, Vlachopoulos et al. \[[@B27]\] have shown that acute systemic inflammation causes an increase in arterial stiffness and a decrease in wave reflection in healthy individuals. This difference may arise from the fact that these parameters reflect different aspects of arterial stiffness. AIx\@75 is primarily determined by the magnitude and timing of reflected pressure waves, which depends on the tone of the resistance arteries \[[@B28]\]. The carotid-femoral PWV is a measure of elastic-type large artery stiffness, which depends on the structural remodeling of large elastic arteries \[[@B4]\]. Therefore, the observed increased PWV but not AIx\@75 in patients with MAC is understandable, probably due to the more prominent impact of MAC on the aorta than the peripheral arteries, and this should also be considered.

The existence of an association between MAC and mortality and cardiovascular disease is well documented \[[@B5],[@B6],[@B29]\]. In this respect, Bozbas et al. \[[@B8]\] demonstrated that coronary microvascular function is impaired in patients with MAC. Also, MAC has been shown to be associated with increased left atrial diameter \[[@B7]\], increased incidence of atrial fibrillation \[[@B30]\], aortic atheroma \[[@B6]\] and conduction defects \[[@B31]\]. In addition to these findings, we successfully identified a significant relationship between MAC and altered vascular function in the current study.

The present study has some limitations, which include the small number of patients involved. Furthermore, since arterial stiffness, the main parameter of our study, reflects structural and functional changes of large arteries, it is difficult to predict all systemic factors and other impacts on vessel structures, and this fact should also be considered when interpreting our results.

Conclusion {#sec1_5}
==========

MAC was independently associated with PWV and may contribute significantly to the development of arterial damage. For a more conclusive statement on the relationship between MAC and arterial stiffness, there is a need for further larger-scale studies.
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###### 

Clinical characteristics and laboratory values of the study population

                             MAC (n = 42)   Control (n = 41)   p
  -------------------------- -------------- ------------------ ------
  Age, years                 68 ± 6         66 ± 6             0.1
  Male, %                    34             39                 0.1
  Hypertension, %            67             66                 0.9
  Diabetes mellitus, %       26             27                 0.9
  Smoking, %                 21             22                 0.9
  Glucose, mg/dl             104 ± 34       106 ± 25           0.7
  Creatinine, mg/dl          0.84 ± 0.23    0.89 ± 0.17        0.3
  Body mass index            30 ± 4         31 ± 4             0.7
  Heart rate, bpm            66 ± 10        68 ± 11            0.4
  Systolic BP, mm Hg         138 ± 18       129 ± 18           0.02
  Diastolic BP, mm Hg        78 ± 12        79 ± 12            0.5
  Mean BP, mm Hg             99 ± 13        98 ± 14            0.7
  LDL cholesterol, mg/dl     135 ± 41       132 ± 26           0.6
  HDL cholesterol, mg/dl     43 ± 10        45 ± 10            0.4
  Total cholesterol, mg/dl   195 ± 49       205 ± 32           0.3
  Triglyceride, mg/dl        162 ± 69       175 ± 77           0.4
  Aspirin, %                 50             41                 0.4
  β-Blockers, %              33             29                 0.7
  ACE inhibitors, %          43             41                 0.9
  ARB, %                     24             27                 0.7
  Diuretic, %                14             20                 0.5
  Ca channel blocker, %      10             2                  0.2
  Statins, %                 21             20                 0.8

BP = Blood pressure; LDL = low-density lipoprotein; HDL = high-density lipoprotein; ACE = Angiotensin-converting enzyme; ARB = angiotensin receptor blockers.

###### 

Pulse wave analysis and velocity in the study groups

                                   MAC (n = 42)   Control (n = 41)   p
  -------------------------------- -------------- ------------------ ----------
  Central aortic pressure, mm Hg                                     
   Systolic                        127 ± 16       121 ± 18           0.11
   Diastolic                       79 ± 12        80 ± 12            0.51
   Mean                            99 ± 13        98 ± 14            0.7
  PWV, m/s                         12.2 ± 2.3     10.1 ± 1.3         \<0.0001
  AP, mm Hg                        16 ± 6         16 ± 10            0.81
  AIx\@75, %                       28 ± 10        29 ± 10            0.59

###### 

Bivariate correlation analysis between PWV and other variables

                      r       p
  ------------------- ------- -------
  Age                 0.1     0.3
  Glucose             0.08    0.4
  Creatinine          0.1     0.2
  Total cholesterol   −0.07   0.4
  Triglyceride        −0.03   0.7
  LDL cholesterol     −0.02   0.8
  HDL cholesterol     −0.09   0.4
  Body mass index     −0.12   0.2
  Brachial SP         0.31    0.003
  Brachial DP         0.2     0.06
  Brachial MP         0.21    0.05
  Aortic SP           0.24    0.02
  Aortic DP           0.18    0.08
  Aortic MP           0.21    0.05

LDL = Low-density lipoprotein; HDL = high-density lipoprotein; SP = systolic pressure; DP = diastolic pressure; MP = mean pressure.

###### 

Baseline characteristic and PWV

                       PWV, m/s     p            
  -------------------- ------------ ------------ -----
  Male                 11.6 ± 2     10.9 ± 2.2   0.1
  Hypertension         11.2 ± 2     11.1 ± 2.4   0.8
  Diabetes mellitus    10.8 ± 1.7   11.3 ± 2.3   0.4
  Smoking              11.3 ± 2.1   11.1 ± 2.2   0.7
  Aspirin              11.1 ± 1.9   11.2 ± 2.4   0.8
  β-Blockers           11.1 ± 1.4   11.2 ± 1.4   0.8
  ACE                  11.0 ± 2     11.3 ± 2.3   0.5
  ARB                  10.6 ± 1.6   11.3 ± 2.3   0.1
  Statin               11 ± 1.4     11.2 ± 2.3   0.7
  Diuretic             11.1 ± 2.2   11.1 ± 2.1   0.9
  Ca channel blocker   12.9 ± 2.5   11.0 ± 2.1   01

ACE = Angiotensin-converting enzyme; ARB = angiotensin receptor blockers; + = present; -- = absent.
